| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/MD.0B013E3181C10773 |
| P698 | PubMed publication ID | 19910750 |
| P50 | author | Javier Martin | Q55089349 |
| Ricardo Blanco | Q73343789 | ||
| P2093 | author name string | Miguel A Gonzalez-Gay | |
| Carlos Gonzalez-Juanatey | |||
| Javier Llorca | |||
| Tomas R Vazquez-Rodriguez | |||
| Jose A Miranda-Filloy | |||
| Trinidad Dierssen | |||
| Ines Vaqueiro | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| patient | Q181600 | ||
| cardiovascular disease | Q389735 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 358-365 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease | |
| P478 | volume | 88 |
| Q37686803 | Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. |
| Q51728489 | Aerobic capacity and its correlates in patients with ankylosing spondylitis. |
| Q36151574 | Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy |
| Q41612327 | Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients |
| Q44738419 | Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. |
| Q33706485 | Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. |
| Q90651753 | Assessing Endothelial Dysfunction in Patients with Ankylosing Spondylitis |
| Q90479817 | Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis |
| Q89417229 | Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study |
| Q58743766 | Association of circulating calprotectin with lipid profile in axial spondyloarthritis |
| Q38185646 | Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? |
| Q50355546 | Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. |
| Q38025994 | Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q33709082 | Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis |
| Q35496549 | Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation |
| Q64079453 | Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis |
| Q38936667 | Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. |
| Q44925048 | Carotid intima-media thickness in spondyloarthritis patients |
| Q47557825 | Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa |
| Q35557952 | Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease |
| Q57605596 | DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen |
| Q58694922 | Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound |
| Q89444267 | Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-α antagonists and healthy matched controls |
| Q51373483 | Evaluation of various endothelial biomarkers in ankylosing spondylitis. |
| Q48007635 | Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease |
| Q64111747 | Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis |
| Q34250990 | IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy |
| Q34731291 | Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study. |
| Q35142805 | Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. |
| Q36727576 | Is there a relationship between endothelial nitric oxide synthase gene polymorphisms and ankylosing spondylitis? |
| Q37768157 | Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies |
| Q37088350 | Low vaspin levels are related to endothelial dysfunction in patients with ankylosing spondylitis |
| Q38271745 | Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy |
| Q36891953 | Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study |
| Q96430987 | Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis |
| Q33747796 | Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect |
| Q36943007 | Predictors of Atherosclerosis in Ankylosing Spondylitis |
| Q51389843 | Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis |
| Q40324538 | Radiographic progression is associated with increased cardiovascular risk in patients with axial spondyloarthritis |
| Q38911778 | Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis |
| Q55281285 | Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. |
| Q40065441 | Sex and Cardiovascular Involvement in Inflammatory Joint Diseases |
| Q54473799 | Subclinical atherosclerosis in ankylosing spondylitis: is there a role for inflammation? |
| Q47818153 | The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis |
| Q53095551 | The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial. |
| Q46468090 | Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis |
| Q34164481 | Validated methods for assessment of subclinical atherosclerosis in rheumatology |
Search more.